Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson announces significant progress towards its climate goals - 100% renewable electricity for all sites in the United States, Canada and Europe by 2023

12/01/2021 | 09:34am EST

NEW BRUNSWICK, N.J. - Johnson & Johnson announced that the Company has executed a power purchase agreement (PPA) in the United States (U.S.), showing continued acceleration towards its ambitious goal to procure 100% renewable electricity for all Johnson & Johnson operations by 2025. With this new deal, Johnson & Johnson expects that it will source the equivalent of 100% of the Company's electricity in the U.S. and Canada from wind and solar power by 2023[1].

The new agreement will be comprised of a solar array in Southern Texas for a total generation capacity of 55 megawatts (MW) or approximately 117,000 megawatt hours (MWh) of renewable electricity annually. The agreement was signed in coordination with Orsted, and the solar installation is currently being built.

This adds to existing on-site and off-site renewable projects that currently provide about 70% of Johnson & Johnson's electricity needs in the U.S. and Canada. Additionally, the Company announced a deal earlier in the year for solar power at its Jacksonville, Florida facility. Johnson & Johnson Vision's production site in Limerick, Ireland is already powered by wind, so when the Jacksonville project comes online in 2022 all ACUVUE Brand contact lenses are expected to be made using 100% renewable electricity.

'Last year we announced our most ambitious climate goals to date, including an accelerated renewable electricity goal. We are wasting no time making progress because we know there is no time to waste - the world needs bold climate action to advance both human and planetary health,' said Paulette Frank, Chief Sustainability Officer, Johnson & Johnson.

This North America deal follows the completion of three PPAs in Europe for wind and solar installations, announced in July, that are expected to take Johnson & Johnson to the equivalent of 100% renewable electricity for all operations in Europe by 2023[2].

Johnson & Johnson has a longstanding commitment to environmental health, including two decades of setting and achieving public climate commitments. Johnson & Johnson's current Health for Humanity Climate Goals are to source 100% of the Company's electricity from renewable sources by 2025, to achieve carbon neutrality in its global operations by 2030 and to reduce upstream, value chain (Scope 3) emissions by 20% by 2030 (from 2016 levels).

To date, the Company has built over 50 on-site renewable energy systems on properties in 14 countries and has executed 15 deals for off-site renewable electricity procurement. At the end of 2020, 54% of Johnson & Johnson's global electricity came from renewable sources.

Read more about Johnson & Johnson's Health for Humanity Goals


Johnson & Johnson is also a proud signatory of the Race to Zero/ Business Ambition for 1.5-degreeC campaign with an ambition to reach net zero carbon emissions across its value chain by 2045.

About Johnson & Johnson

At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities, and forward progress. That's why, for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based healthcare company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body, and environment within reach of everyone, everywhere. We are blending our heart, science, and ingenuity to profoundly change the trajectory of health for humanity. Learn more at www.jnj.com. Follow us at @JNJNews.

Cautionary Note Regarding Forward-Looking Statements

This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Third-party trademarks used herein are trademarks of their respective owners.

[1] Based on current properties owned/leased by Johnson & Johnson within our operational control; does not include Puerto Rico.

[2] Based on current properties owned/leased by Johnson & Johnson within our operational control.



Lisa Cannellos

E: LCannel1@ITS.JNJ.com


Jennifer McIntyre

T: +1 732-524-3922

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
05:18aValneva Shares Suffer as Coronavirus Vaccine Seen Arriving Too Late
01/17Johnson & Johnson Statement on New Mexico Opioid Settlement Agreement
01/17Midatech Pharma, Janssen Extend R&D Partnership On Experimental Medicine
01/14European Medicines Agency Asks AstraZeneca, Johnson & Johnson To Add Spinal Inflammatio..
01/13Divco West Real Estate Services, LLC acquired 143,000 square feet, 5000 Shoreline Court..
01/12Johnson & Johnson's COVID-19 Vaccine Fact Sheet Updated to Include Risk of Rare Bleedin..
01/12South African Institute To Study Effects Of Pfizer, BioNTech, Johnson & Johnson Booster..
01/11US FDA Adds Risk of Rare Bleeding Disorder to Johnson & Johnson COVID-19 Jab's Fact She..
01/11Mix and Match Covid-19 Vaccine Study to Take Place in Mozambique
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 306 M - -
Net income 2021 22 542 M - -
Net Debt 2021 596 M - -
P/E ratio 2021 19,8x
Yield 2021 2,48%
Capitalization 440 B 440 B -
EV / Sales 2021 4,67x
EV / Sales 2022 4,35x
Nbr of Employees 134 500
Free-Float 84,3%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 167,10 $
Average target price 183,50 $
Spread / Average Target 9,81%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Alex Gorsky Executive Chairman
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
NOVO NORDISK A/S-13.80%219 759